Odyssey’s Post

✨ Positive phase II/III topline results ✨💊🔬   We are proud to announce that our potentially pivotal study 008A with Evenamide in #schizophrenia patients not benefitting from their current antipsychotic treatments has met its primary endpoint and key secondary endpoint. Evenamide was well tolerated, with no safety concerns identified.   Ravi Anand, our Chief Medical Officer, explained: “This is the first major international study to demonstrate the significant benefit of adding a new chemical entity (NCE) to poorly responding, compliant schizophrenia patients being treated with a second-generation antipsychotic. It is also the first demonstration of efficacy in a placebo-controlled trial of a NCE acting exclusively through glutamaergic inhibition. These results, together with the recently reported one-year efficacy results in treatment-resistant patients, substantiate the pivotal role of glutamate in finding new therapeutic options for schizophrenia patients.   The management team will be available to discuss the results from the study during a conference call, today ,April 30, 2024, at 3 pm CET/ 9 am ET Find all the details here: https://lnkd.in/ebHUW5UC #Newron #NovelTherapies #results #evenamide #schizophrenia

"Research into substance use disorder treatments is complex and evolving, uniquely shaped by scientific advancements, societal attitudes, and the changing nature of substance use disorders themselves." AiCure's latest blog covers how our smartphone-based platform was used in a Substance Use Disorder (SUD) trial to improve treatment adherence and collect daily reports on drug and alcohol use. This approach offers several advantages over traditional methods, making it a powerful tool for SUD clinical trial teams. Read the full blog here: https://lnkd.in/d92dEARE #ClinicalTrials #MedicationAdherence #HealthcareInnovation #substanceusedisorder

New from the CWMH Blog: Phase 2 Clinical Trial Examines the Efficacy of a Novel Psychedelic for the Treatment of Postpartum Depression https://buff.ly/4d0BUi5

FDA clears first digital treatment for depression, but experts caution that research is still early https://lnkd.in/gda5VKwM. Calmdown there is still testing that needs to be done before a final rollout is released. Just as a digital treatment a doctor will prescribe a mix with a actual therapist with a digital treatment with a follow-up appointment to see how the digital treatment with a therapist appointment with a 6 month check up

NON-CONSENSUAL OPIOID DEPRESCRIBING IS NOT JUSTIFIED. Long-term opioids are safe and effective in the management of chronic non-cancer pain when used APPROPRIATELY in a significant subgroup of people. Yet popular opinion in medical circles these days in the Western world, seems to be in favour of introducing mandatory policies of involuntary or non-consensual opioid tapering across the board, irrespective of the benefits for many people with Severe Chronic Secondary Pain. The following American Analysis clearly outlines why "harm to some individuals undergoing forced taper" is a valid concern, and gives examples why a one-size-fits-all approach is "not Justified Clinically or Ethically." Australian policy makers should take note, and NOT force-taper those chronic pain patients who, on balance, show beneficial outcomes when on longterm opioid therapy [LTOT]. #Australia #America #painrelief #nonconsensual #forcedtapers #opioidtapering #deprescribing #chronicsecondarypain #severedisablingpain #persistentpain #opioidguidelines #chronicpainmanagement #noonesizefitsall #patientadvocacy #multidisciplinarycare #selfmanagement #medicalgaslighting #undertreatedpain #prescriptionopioids #opioidcrisis #opioidepidemic #addiction #dependence #overdose #opioidrestrictions #opiophobia #opioidhysteria #holisticcare #qualityoflife #humanrights #education #stopthestigma #dontpunishpain https://lnkd.in/gBwEXhqX

Pain researchers must learn from the opioid crisis. In 2022, over 80,000 people in the U.S. died from opioid overdoses. To combat this crisis, we must shift from opioid-based painkillers to safer alternatives. Scientists are now focusing on non-opioid alternatives that target specific pain mechanisms, thanks to advancements in drug screening methods like phenotypic screening and AI-driven techniques. These approaches are helping to discover pain treatments that are effective without the risk of addiction. It's time to move beyond opioids and prioritize safer, more targeted pain relief solutions. Read the entire article here to learn more: https://lnkd.in/g3tp2Bg9 #OpioidCrisis #PainManagement #SaferPainRelief #EndTheEpidemic

It was a very honor and a source of pride to have started my experience in NEURIMPULSE srl partecipating in Cadaverlab in order to develop new approaches and techniques about #PeripheralNerveStimulation! #PNS #NEURIMPULSE

The U.S. #FDA recently granted Breakthrough Therapy Designation #BTD to Cybin’s #CYB003 for the treatment of Major Depressive Disorder #MDD. BTD is designed to expedite the development and review of drugs intended to treat a serious condition where preliminary clinical evidence indicates they may demonstrate substantial improvement over available therapy. A drug that receives BTD is eligible for increased access to FDA guidance on future trial design, with the potential to significantly reduce development timelines. BTD is a rare distinction: there are around 100 requests per year and historically only one-third were approved. Learn more: https://lnkd.in/g_zMznwY #FDA #BTD #Psilocybin #Depression #MentalHealthInnovation

The individual-level prediction tool described in this study may be a universal risk measure for return to opioid use by treatment week 3. Interventions to prevent return to regular use should focus on this critical early treatment period. https://ja.ma/3NPQP49

This study reveals that classic psychedelics like LSD and psilocybin can significantly reduce OCD symptoms. The research highlights the importance of dose and the intensity of the psychedelic experience in achieving therapeutic benefits, suggesting a promising alternative for OCD treatment. #OCD #psychedelics https://lnkd.in/dzjn2RQt